Understanding Immune Tolerance: New Hope for Autoimmune Diseases and Organ Transplants. a81

Can we help?

This comprehensive review explains how our immune system maintains balance between fighting infections and avoiding attacks on our own body—a process called immune tolerance. Recent breakthroughs in understanding this balance have led to new treatments for autoimmune diseases, allergies, and organ transplantation that may provide long-term benefits with short-term therapy. The article details how checkpoint inhibitors both treat cancer and can cause autoimmune side effects, highlighting the delicate equilibrium required for immune health.

Understanding Immune Tolerance: New Hope for Autoimmune Diseases and Organ Transplants

Table of Contents

Introduction: The Immune Balance Challenge

For decades, scientists have sought to understand how our immune system learns to distinguish between foreign invaders and our own tissues—a process called immune tolerance. When this system fails, it can lead to serious conditions like food allergies, autoimmune diseases (where the body attacks itself), and organ transplant rejection.

Although early experiments in tolerance began in the 1950s, developing effective treatments has proven challenging despite advances in understanding how our immune system works. However, recent breakthroughs have led to successful new therapies for organ transplantation, allergic conditions, and autoimmune diseases.

Novel peptide drugs, antibodies that target specific immune cells, and cell therapies now offer the possibility of short-term treatments that provide long-term benefits, potentially eliminating the need for continuous medication. This represents a major shift from traditional approaches that required lifelong immunosuppression with significant side effects.

How Your Body Maintains Immune Tolerance

Your immune system uses multiple sophisticated mechanisms to maintain tolerance. The term "unresponsiveness" in immune tolerance refers to several protective states where potentially harmful immune cells are either deactivated, eliminated, or converted into protective cells through regulatory cells, changes in cell development, or immune barriers.

Current approaches to developing tolerance-inducing drugs aim to treat and prevent allergic and autoimmune diseases while enabling organ and tissue transplantation without lifelong immunosuppression. Some of the most successful recent therapies actually break tolerance to treat cancers that hide behind tolerogenic signals, though these treatments can sometimes trigger autoimmune conditions.

This delicate balance between breaking tolerance to treat tumors and maintaining overall immune homeostasis underscores the complexity of immune regulation. The review focuses specifically on T cells and their dual role in both causing and suppressing immune reactions, as they represent promising targets for new therapies.

The Thymus: Your Body's Immune Training Center

The thymus gland serves as the birthplace and training ground for T cells, which are crucial white blood cells that coordinate immune responses. In the early 1960s, researchers identified two distinct types of immune cells: T cells and B cells, which form the foundation of our adaptive immune system.

T cells perform several critical functions: they help B cells produce antibodies, directly kill infected or foreign tissues, and regulate immune responses. Each T cell has a unique receptor capable of recognizing specific targets—this diversity allows your immune system to respond to countless potential threats.

The process of T-cell development involves two crucial selection steps in the thymus. First, positive selection ensures T cells can recognize foreign particles presented by your body's own MHC molecules (major histocompatibility complex molecules that display protein fragments to immune cells).

Second, negative selection eliminates T cells that react too strongly against your own tissues. Specialized cells called medullary thymic epithelial cells (mTECs) express a protein called AIRE (autoimmune regulator) that enables them to display thousands of tissue-specific proteins to developing T cells, effectively weeding out self-reactive cells.

The critical importance of this process is demonstrated by autoimmune polyglandular syndrome type 1 (APS1), a severe multi-organ autoimmune condition that occurs in people with AIRE gene mutations. This shows how central thymic education is to preventing autoimmune disease.

Peripheral Tolerance: Backup Security System

Despite the thymus's efficiency, some self-reactive T cells escape into the periphery, requiring additional safety mechanisms. Peripheral tolerance involves multiple cell types and processes that control immune responses outside the thymus.

T-cell activation requires two signals: first through the T-cell receptor recognizing its target, and second through costimulatory molecules like CD28 interacting with CD80/CD86 on antigen-presenting cells. Blocking these costimulatory pathways can induce antigen-specific tolerance, as demonstrated in animal models of autoimmune disorders and transplantation.

Equally important are checkpoint pathways that shut down immune activation. Molecules like CTLA-4 and PD-1 (programmed death 1) act as brakes on the immune system. When these checkpoints are inhibited—as in cancer immunotherapy—autoimmunity can worsen, demonstrating their role in maintaining tolerance.

Checkpoint inhibitors have revolutionized cancer treatment for conditions like melanoma and non-small cell lung cancer, but they can also cause autoimmune side effects, highlighting the delicate balance between effective immunity and harmful autoimmunity.

Regulatory T Cells: Your Body's Peacekeepers

Specialized cells called regulatory T cells (Tregs) play a fundamental role in maintaining immune balance. These cells develop from self-reactive T cells that express a master control protein called FOXP3 (forkhead box P3), which programs them to suppress rather than attack.

There are two main types of Tregs: thymus-derived Tregs (tTregs) that develop in the thymus during negative selection, and peripherally derived Tregs (pTregs) that develop in tissues from conventional T cells exposed to suppressive factors. The combination of these cell types, along with other regulatory cells, provides broad protection against autoimmune reactions.

Disruption of FOXP3 function, either through genetic mutations (as in IPEX syndrome) or pharmacological interference, leads to severe autoimmune disorders that are often fatal in early childhood without bone marrow transplantation. This demonstrates the critical importance of Tregs in maintaining immune homeostasis.

Tregs employ multiple suppression mechanisms: they express high levels of CTLA-4 which blocks costimulation, produce anti-inflammatory cytokines like interleukin-10 and TGF-β (transforming growth factor beta), and can convert ATP to adenosine which suppresses immune responses. They also influence the gut microbiome, and microbial products like short-chain fatty acids can enhance their function.

New Tolerance-Inducing Therapies

Historically, autoimmune diseases and transplant rejection were treated with broad immunosuppressants that carried significant side effects. New approaches aim for more targeted tolerance induction without continuous therapy.

Hematopoietic stem cell transplantation (HSCT) can "reboot" the immune system by eliminating autoreactive cells and allowing new immune cells to develop tolerance during recovery. Autologous HSCT has shown promise in halting progression of multiple sclerosis, while combining autologous and donor-derived HSCT can create lasting tolerance to donor tissues while maintaining immune function.

Immune cell depletion approaches using antibodies like alemtuzumab (anti-CD52), rituximab, ocrelizumab, and obinutuzumab (which target B cells) have successfully slowed disease progression in some autoimmune conditions. These treatments work partly by eliminating autoreactive B cells that efficiently present self-antigens to T cells.

Additional approaches include costimulatory blockade using monoclonal antibodies and soluble forms of checkpoint receptors, checkpoint agonists for autoimmune diseases, and manipulation of regulatory T cells through expansion or therapeutic administration.

Clinical Applications and Implications

The new understanding of immune tolerance mechanisms has significant implications for patients with autoimmune diseases, allergies, and those requiring organ transplants. Instead of lifelong immunosuppression with its associated risks, short-term tolerance-inducing treatments may provide long-term benefits.

For cancer patients, checkpoint inhibitors have transformed treatment outcomes but come with autoimmune side effects that require careful management. Understanding the balance between breaking tolerance to attack tumors and maintaining overall immune homeostasis is crucial for optimizing these therapies.

The connection between the immune system and gut microbiome opens new therapeutic possibilities. Microbial products like short-chain fatty acids can enhance regulatory T cell function, suggesting dietary interventions might complement medical treatments for immune disorders.

Age-related changes in tolerance mechanisms suggest that treatment approaches might need to differ between children and adults, with peripheral tolerance pathways becoming more important as the thymus involutes in adulthood.

Study Limitations and Challenges

While significant progress has been made, several challenges remain in translating tolerance research into clinical practice. Many successful approaches in animal models have not yet demonstrated similar efficacy in human trials.

Individual variability in immune responses and genetic backgrounds means that tolerance-inducing strategies may need to be personalized. The complexity of immune regulation involving multiple redundant pathways makes targeting single components challenging.

Long-term safety data for newer tolerance-inducing approaches is still limited, particularly regarding cancer risk from prolonged immune modulation. The delicate balance between effective immunity and tolerance means that interventions must be carefully calibrated to avoid excessive immunosuppression or autoimmunity.

Additionally, most current approaches still require some form of initial immune suppression or conditioning, which carries its own risks and side effects. Developing less invasive tolerance induction methods remains an important goal.

Recommendations for Patients

For patients dealing with autoimmune conditions, allergies, or organ transplantation, these advances in understanding immune tolerance offer hope for more targeted and effective treatments with fewer side effects. Here's what patients should know:

  1. Discuss new treatment options with your healthcare provider, including whether you might be a candidate for newer tolerance-inducing therapies rather than traditional broad immunosuppressants.
  2. Understand the balance between immune activation and suppression—treatments that enhance immunity against cancer might increase autoimmune risk, while those that suppress autoimmunity might affect cancer surveillance.
  3. Consider the gut-immune connection—emerging research suggests that diet and microbiome health may influence immune tolerance, so discuss nutritional approaches with your care team.
  4. Participate in clinical trials when appropriate, as many new tolerance-inducing approaches are still in development and need patient volunteers to advance.
  5. Monitor for side effects carefully with any immune-modulating treatment, and report any new symptoms promptly to your healthcare provider.

While these advances are promising, patients should work closely with their medical team to determine the most appropriate approach for their specific condition, considering factors like disease severity, treatment history, and overall health status.

Source Information

Original Article Title: Tolerance in the Age of Immunotherapy

Authors: Jeffrey A. Bluestone, Ph.D., and Mark Anderson, M.D., Ph.D.

Publication: The New England Journal of Medicine, September 17, 2020

DOI: 10.1056/NEJMra1911109

This patient-friendly article is based on peer-reviewed research and aims to make complex immunological concepts accessible to educated patients while preserving all significant scientific content from the original publication.